experimental osteoporosis drug odanacatib has shown that it
reduces fracture risk, prompting outside monitors to recommend
that the study be stopped early so that all patients in the
trial can be offered the treatment.
Wednesday, July 11, 2012
UPDATE 1-Merck bone drug shows clear benefits, trial halted
July 11 (Reuters) - A pivotal trial of Merck & Co's
experimental osteoporosis drug odanacatib has shown that it
reduces fracture risk, prompting outside monitors to recommend
that the study be stopped early so that all patients in the
trial can be offered the treatment.
experimental osteoporosis drug odanacatib has shown that it
reduces fracture risk, prompting outside monitors to recommend
that the study be stopped early so that all patients in the
trial can be offered the treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment